Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States. METHODS: We analyzed serum samples from four groups of subjects for IgE antibodies against cetuximab: pretreatment samples from 76 case subjects who had been treated with cetuximab at multiple centers, predominantly in Tennessee, Arkansas, and North Carolina; samples from 72 control subjects in Tennessee; samples from 49 control subjects with cancer in northern California; and samples from 341 female control subjects in Boston. RESULTS: Among 76 cetuximab-treated subjects, 25 had a hypersensitivity reaction to the drug. IgE antibodies against cetuximab were found in pretreatment samples from 17 of these subjects; only 1 of 51 subjects who did not have a hypersensitivity reaction had such antibodies (P<0.001). IgE antibodies against cetuximab were found in 15 of 72 samples (20.8%) from control subjects in Tennessee, in 3 of 49 samples (6.1%) from northern California, and in 2 of 341 samples (0.6%) from Boston. The IgE antibodies were shown to be specific for an oligosaccharide, galactose-alpha-1,3-galactose, which is present on the Fab portion of the cetuximab heavy chain. CONCLUSIONS: In most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies against cetuximab were present in serum before therapy. The antibodies were specific for galactose-alpha-1,3-galactose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Humans also lack the ability to produce the Galα1–3Galβ1–4GlcNAc–R epitope, which is common in murine cells, and this has been shown to induce anaphylaxis [8,33].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Murine cells can also produce α-gal and Neu5Gc at considerably higher levels than hamster cells, increasing the risks of immunogenicity (Tangvoranuntakul et al., 2003;Chung et al., 2008;Macher and Galili, 2008;Padler-Karavani et al., 2008;Ghaderi et al., 2012).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Chung et al., 2008
Experimental — accuracy not yet measuredIn the citing paper
“However, anti-α-Gal IgE antibodies can cause allergic reactions, such as anaphylaxis, against cetuximab, a therapeutic monoclonal antibody targeting epidermal growth factor receptor (EGFR)”
From ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies (2023) · cites this paper as Chung et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
(1945) · Harvard University Press eBooks · doi:10.4159/harvard.9780674184220 · Cited by 1,078
The diagnosis and management of anaphylaxis: An updated practice parameter
LIEBERMAN, P., KEMP, S., OPPENHEIMER, J., LANG, D., BERNSTEIN, I., NICKLAS, R., ANDERSON, J., BERNSTEIN, D., BERNSTEIN, J., & FINK, J. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.010 · Cited by 667
Symposium on the Definition and Management of Anaphylaxis: Summary report
Sampson, H. A., Muñoz-Furlong, A., Bock, S. A., Schmitt, C., Bass, R., Chowdhury, B. A., Decker, W. W., Furlong, T. J., Galli, S. J., Golden, D. B., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.009 · Cited by 641
The incidence and management of infusion reactions to infliximab: a large center experience
Cheifetz, A. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00231-4 · Cited by 491
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
Holgate, S., Casale, T., Wenzel, S., Bousquet, J., Deniz, Y., & Reisner, C. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.053 · Cited by 466
Research works printed but not linked: 1
- Carolina; association with atopic history. J Clin Oncol 2007;25:3644-8.
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
Human milk oligosaccharides: Every baby needs a sugar mama
Bode, L. (2012) · Glycobiology · doi:10.1093/glycob/cws074 · Cited by 1,809
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Drug Allergy: An Updated Practice Parameter
(2010) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2010.08.002 · Cited by 957
EAACI Molecular Allergology User's Guide
Matricardi, P. M., Kleine‐Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer‐Weber, B., et al. (2016) · Pediatric Allergy and Immunology · doi:10.1111/pai.12563 · Cited by 932
Self-citationGlycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
Harding, F. A., Stickler, M. M., Razo, J., & DuBridge, R. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 737
The diagnosis and management of anaphylaxis practice parameter: 2010 Update
Lieberman, P., Nicklas, R. A., Oppenheimer, J., Kemp, S. F., Lang, D. M., Bernstein, D. I., Bernstein, J. A., Burks, A. W., Feldweg, A. M., Fink, J. N., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.06.022 · Cited by 739
Commins, S. P., Satinover, S. M., Hosen, J., Mozena, J., Borish, L., Lewis, B. D., Woodfolk, J. A., & Platts-Mills, T. A. E. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.10.052 · Cited by 690
Self-citationCommins, S. P., James, H. R., Kelly, L. A., Pochan, S. L., Workman, L. J., Perzanowski, M. S., Kocan, K. M., Fahy, J. V., Nganga, L. W., Ronmark, E., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.02.019 · Cited by 642
Self-citationDrug allergy: A 2022 practice parameter update
Khan, D. A., Banerji, A., Blumenthal, K. G., Phillips, E. J., Solensky, R., White, A. A., Bernstein, J. A., Chu, D. K., Ellis, A. K., Golden, D. B. K., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.08.028 · Cited by 563
Panel), E. P. O. G. M. O. (. (2010) · EFSA Journal · doi:10.2903/j.efsa.2010.1700 · Cited by 608
Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars
Berkowitz, S. A., Engen, J. R., Mazzeo, J. R., & Jones, G. B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3746 · Cited by 529
Factors affecting the development of adverse drug reactions (Review article)
Alomar, M. J. (2014) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.02.003 · Cited by 484
Piawah, S., & Venook, A. P. (2019) · Cancer · doi:10.1002/cncr.32163 · Cited by 488
Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives
Dumont, J., Euwart, D., Mei, B., Estes, S., & Kshirsagar, R. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1084266 · Cited by 483
Anaphylaxis—a practice parameter update 2015
Lieberman, P., Nicklas, R. A., Randolph, C., Oppenheimer, J., Bernstein, D., Bernstein, J., Ellis, A., Golden, D. B. K., Greenberger, P., Kemp, S., et al. (2015) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2015.07.019 · Cited by 474
Emerging principles for the therapeutic exploitation of glycosylation
Dalziel, M., Crispin, M., Scanlan, C. N., Zitzmann, N., & Dwek, R. A. (2014) · Science · doi:10.1126/science.1235681 · Cited by 447
A WAO - ARIA - GA²LEN consensus document on molecular-based allergy diagnostics
Canonica, G. W., Ansotegui, I. J., Pawankar, R., Schmid-Grendelmeier, P., van Hage, M., Baena-Cagnani, C. E., Melioli, G., Nunes, C., Passalacqua, G., Rosenwasser, L., et al. (2013) · World Allergy Organization Journal · doi:10.1186/1939-4551-6-17 · Cited by 432
“Testing for α-Gal before administration of cetuximab should therefore be considered [64].”
BackgroundSiena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., & Bardelli, A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 429
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428
Plant‐specific glycosylation patterns in the context of therapeutic protein production
Gomord, V., Fitchette, A., Menu‐Bouaouiche, L., Saint‐Jore‐Dupas, C., Plasson, C., Michaud, D., & Faye, L. (2010) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2009.00497.x · Cited by 418
Fc glycans of therapeutic antibodies as critical quality attributes
Reusch, D., & Tejada, M. L. (2015) · Glycobiology · doi:10.1093/glycob/cwv065 · Cited by 404
Maintaining safety with SARS-CoV-2 vaccines
Castells, M. C., & Phillips, E. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2035343 · Cited by 395
Yang, Q., Jacobs, T. M., McCallen, J. D., Moore, D. T., Huckaby, J. T., Edelstein, J. N., & Lai, S. K. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03437 · Cited by 370
Simons, F. E. R. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.12.981 · Cited by 368
Expression systems for therapeutic glycoprotein production
Durocher, Y., & Butler, M. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.008 · Cited by 386
The alpha-gal story: Lessons learned from connecting the dots
Steinke, J. W., Platts-Mills, T. A. E., & Commins, S. P. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1947 · Cited by 374
Self-citationImplications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins
Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., & Varki, A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1651 · Cited by 372
Skin cancer in solid organ transplant recipients: Advances in therapy and management
O’Reilly Zwald, F., & Brown, M. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.11.063 · Cited by 354
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
Jefferis, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.04.007 · Cited by 330
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Stroud, C. R., Hegde, A., Cherry, C., Naqash, A. R., Sharma, N., Addepalli, S., Cherukuri, S., Parent, T., Hardin, J., & Walker, P. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217745144 · Cited by 331
Mayorga, C., Celik, G., Rouzaire, P., Whitaker, P., Bonadonna, P., Rodrigues‐Cernadas, J., Vultaggio, A., Brockow, K., Caubet, J. C., Makowska, J., et al. (2016) · Allergy · doi:10.1111/all.12886 · Cited by 314
Skin cancer in solid organ transplant recipients: Advances in therapy and management
O’Reilly Zwald, F., & Brown, M. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.11.062 · Cited by 311
Ghaderi, D., Zhang, M., Hurtado-Ziola, N., & Varki, A. (2012) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-28-147 · Cited by 320
“As mentioned earlier the alpha-Gal epitope on Cetuximab has been shown to induce anaphylaxis in patients triggered by pre-existing anti-Gal IgE antibodies (Chung et al., 2008).”
BackgroundInfluentialGlobal Trends in Anaphylaxis Epidemiology and Clinical Implications
Turner, P. J., Campbell, D. E., Motosue, M. S., & Campbell, R. L. (2020) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.11.027 · Cited by 296
Advances in the assessment and control of the effector functions of therapeutic antibodies
Jiang, X.-R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., Chung, S., Strouse, R., Mire-Sluis, A., & Schenerman, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3365 · Cited by 299
Huhn, C., Selman, M. H. J., Ruhaak, L. R., Deelder, A. M., & Wuhrer, M. (2009) · PROTEOMICS · doi:10.1002/pmic.200800715 · Cited by 301
EAACI Molecular Allergology User's Guide 2.0
Dramburg, S., Hilger, C., Santos, A. F., de las Vecillas, L., Aalberse, R. C., Acevedo, N., Aglas, L., Altmann, F., Arruda, K. L., Asero, R., et al. (2023) · Pediatric Allergy and Immunology · doi:10.1111/pai.13854 · Cited by 298
Self-citationAn association between tick bite reactions and red meat allergy in humans
Van Nunen, S. A., O’Connor, K. S., Clarke, L. R., Boyle, R. X., & Fernando, S. L. (2009) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02533.x · Cited by 286
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296
“Murine cells can also produce α-gal and Neu5Gc at considerably higher levels than hamster cells, increasing the risks of immunogenicity (Tangvoranuntakul et al., 2003; Chung et al., 2008; Macher and Galili, 2008; Padler-Karavani et al., 2008; Ghaderi et al., 2012).”
BackgroundAlt, N., Zhang, T. Y., Motchnik, P., Taticek, R., Quarmby, V., Schlothauer, T., Beck, H., Emrich, T., & Harris, R. J. (2016) · Biologicals · doi:10.1016/j.biologicals.2016.06.005 · Cited by 294
Vaisman-Mentesh, A., Gutierrez-Gonzalez, M., DeKosky, B. J., & Wine, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01951 · Cited by 292
Brennan, P. J., Bouza, T. R., Hsu, F. I., Sloane, D. E., & Castells, M. C. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.009 · Cited by 283
Ganson, N. J., Povsic, T. J., Sullenger, B. A., Alexander, J. H., Zelenkofske, S. L., Sailstad, J. M., Rusconi, C. P., & Hershfield, M. S. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.034 · Cited by 273
Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy
Chung, C. H. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0012 · Cited by 278
Self-citationT-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Jawa, V., Cousens, L. P., Awwad, M., Wakshull, E., Kropshofer, H., & De Groot, A. S. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.006 · Cited by 270
Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C.-H. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 257
Relationship between red meat allergy and sensitization to gelatin and galactose-α-1,3-galactose
Mullins, R. J., James, H., Platts-Mills, T. A. E., & Commins, S. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.02.038 · Cited by 260
Self-citationSafety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
Brennan, F. R., Morton, L. D., Spindeldreher, S., Kiessling, A., Allenspach, R., Hey, A., Müller, P., Frings, W., & Sims, J. (2010) · mAbs · doi:10.4161/mabs.2.3.11782 · Cited by 250
Vultaggio, A., Matucci, A., Nencini, F., Pratesi, S., Parronchi, P., Rossi, O., Romagnani, S., & Maggi, E. (2010) · Allergy · doi:10.1111/j.1398-9995.2009.02280.x · Cited by 238
BSACI guidelines for the management of drug allergy
Mirakian, R., Ewan, P. W., Durham, S. R., Youlten, L. J. F., Dugué, P., Friedmann, P. S., English, J. S., Huber, P. A. J., & Nasser, S. M. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.03155.x · Cited by 240
Anaphylaxis: Recent advances in assessment and treatment
Simons, F. E. R. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.08.025 · Cited by 242
Impact of host cell line choice on glycan profile
Goh, J. B., & Ng, S. K. (2018) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2017.1416577 · Cited by 225
Diagnosis and management of anaphylaxis in precision medicine
Castells, M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.012 · Cited by 242
Clinical development of targeted and immune based anti-cancer therapies
Seebacher, N. A., Stacy, A. E., Porter, G. M., & Merlot, A. M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1094-2 · Cited by 231
Emergency department diagnosis and treatment of anaphylaxis: a practice parameter
Campbell, R. L., Li, J. T. C., Nicklas, R. A., & Sadosty, A. T. (2014) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2014.10.007 · Cited by 229
Yu, R. J., Krantz, M. S., Phillips, E. J., & Stone, C. A. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.09.021 · Cited by 222
Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 234
Pharmacological significance of glycosylation in therapeutic proteins
Li, H., & d’Anjou, M. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.009 · Cited by 231
Khan, D. A., & Solensky, R. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.10.028 · Cited by 227
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications
Kuriakose, A., Chirmule, N., & Nair, P. (2016) · Journal of Immunology Research · doi:10.1155/2016/1298473 · Cited by 227
Current Treatment Options for Metastatic Head and Neck Cancer
Price, K. A. R., & Cohen, E. E. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-011-0176-y · Cited by 225
Diagnosis & management of alpha-gal syndrome: lessons from 2,500 patients
Commins, S. P. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1782745 · Cited by 206
Anti‐Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits
Galili, U. (2013) · Immunology · doi:10.1111/imm.12110 · Cited by 225
Zhang, P., Woen, S., Wang, T., Liau, B., Zhao, S., Chen, C., Yang, Y., Song, Z., Wormald, M. R., Yu, C., et al. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.006 · Cited by 213
Recent advances in mammalian protein production
Bandaranayake, A. D., & Almo, S. C. (2014) · FEBS Letters · doi:10.1016/j.febslet.2013.11.035 · Cited by 222
Mimura, Y., Katoh, T., Saldova, R., O’Flaherty, R., Izumi, T., Mimura-Kimura, Y., Utsunomiya, T., Mizukami, Y., Yamamoto, K., Matsumoto, T., et al. (2018) · Protein & Cell · doi:10.1007/s13238-017-0433-3 · Cited by 217
Recent advances in technology supporting biopharmaceutical production from mammalian cells
Butler, M., & Meneses-Acosta, A. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4451-z · Cited by 210
Diagnosis and Management of Patients with the α-Gal Syndrome
Platts-Mills, T. A. E., Li, R.-C., Keshavarz, B., Smith, A. R., & Wilson, J. M. (2020) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.09.017 · Cited by 197
Self-citationMartins, R. G., Parvathaneni, U., Bauman, J. E., Sharma, A. K., Raez, L. E., Papagikos, M. A., Yunus, F., Kurland, B. F., Eaton, K. D., Liao, J. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3299 · Cited by 206
Hamsten, C., Starkhammar, M., Tran, T. A. T., Johansson, M., Bengtsson, U., Ahlén, G., Sällberg, M., Grönlund, H., & van Hage, M. (2013) · Allergy · doi:10.1111/all.12128 · Cited by 209
Aggregation of Protein Therapeutics Enhances Their Immunogenicity: Causes and Mitigation Strategies
Lundahl, M. L. E., Fogli, S., Colavita, P. E., & Scanlan, E. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00067e · Cited by 212
Commins, S. P., James, H. R., Stevens, W., Pochan, S. L., Land, M. H., King, C., Mozzicato, S., & Platts-Mills, T. A. E. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.01.024 · Cited by 203
Self-citationFully human antibodies from transgenic mouse and phage display platforms
Lonberg, N. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.004 · Cited by 188
Interchangeability of Biosimilars: A European Perspective
Kurki, P., van Aerts, L., Wolff-Holz, E., Giezen, T., Skibeli, V., & Weise, M. (2017) · BioDrugs · doi:10.1007/s40259-017-0210-0 · Cited by 189
Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose
Gramer, M. J., Eckblad, J. J., Donahue, R., Brown, J., Shultz, C., Vickerman, K., Priem, P., van den Bremer, E. T. J., Gerritsen, J., & van Berkel, P. H. C. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23075 · Cited by 193
Visser, J., Feuerstein, I., Stangler, T., Schmiederer, T., Fritsch, C., & Schiestl, M. (2013) · BioDrugs · doi:10.1007/s40259-013-0036-3 · Cited by 185
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses
Baldo, B. (2013) · OncoImmunology · doi:10.4161/onci.26333 · Cited by 191
Ayoub, D., Jabs, W., Resemann, A., Evers, W., Evans, C., Main, L., Baessmann, C., Wagner-Rousset, E., Suckau, D., & Beck, A. (2013) · mAbs · doi:10.4161/mabs.25423 · Cited by 184
Wada, R., Matsui, M., & Kawasaki, N. (2019) · mAbs · doi:10.1080/19420862.2018.1551044 · Cited by 186
van Beers, M. M. C., & Bardor, M. (2012) · Biotechnology Journal · doi:10.1002/biot.201200065 · Cited by 172
The role of biosimilars in the treatment of rheumatic diseases
Dörner, T., Strand, V., Castañeda-Hernández, G., Ferraccioli, G., Isaacs, J. D., Kvien, T. K., Martin-Mola, E., Mittendorf, T., Smolen, J. S., & Burmester, G. R. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202715 · Cited by 178
In vitro and in vivo modifications of recombinant and human IgG antibodies
Liu, H., Ponniah, G., Zhang, H.-M., Nowak, C., Neill, A., Gonzalez-Lopez, N., Patel, R., Cheng, G., Kita, A. Z., & Andrien, B. (2014) · mAbs · doi:10.4161/mabs.29883 · Cited by 168
The choice of mammalian cell host and possibilities for glycosylation engineering
Butler, M., & Spearman, M. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.06.010 · Cited by 175
Red meat allergy in Sweden: Association with tick sensitization and B-negative blood groups
Hamsten, C., Tran, T. A. T., Starkhammar, M., Brauner, A., Commins, S. P., Platts-Mills, T. A. E., & van Hage, M. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.050 · Cited by 174
Self-citationA Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer
Rosen, L. S., Hurwitz, H. I., Wong, M. K., Goldman, J., Mendelson, D. S., Figg, W. D., Spencer, S., Adams, B. J., Alvarez, D., Seon, B. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0098 · Cited by 170
Wilson, J. M., Schuyler, A. J., Workman, L., Gupta, M., James, H. R., Posthumus, J., McGowan, E. C., Commins, S. P., & Platts-Mills, T. A. E. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.03.031 · Cited by 149
Self-citationZhou, Q., & Qiu, H. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.11.029 · Cited by 169
Self-citationCharacterization of isomeric glycan structures by LC‐MS/MS
Veillon, L., Huang, Y., Peng, W., Dong, X., Cho, B. G., & Mechref, Y. (2017) · ELECTROPHORESIS · doi:10.1002/elps.201700042 · Cited by 163
Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines
Roselló, S., Blasco, I., Fabregat, L. G., Cervantes, A. M. R., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx216 · Cited by 168
Vézina, L., Faye, L., Lerouge, P., D’Aoust, M., Marquet‐Blouin, E., Burel, C., Lavoie, P., Bardor, M., & Gomord, V. (2009) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2009.00414.x · Cited by 166
Jawa, V., Terry, F., Gokemeijer, J., Mitra-Kaushik, S., Roberts, B. J., Tourdot, S., & De Groot, A. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01301 · Cited by 152
Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy.
van Rhee, F., Stone, K., Szmania, S. M., Barlogie, B., & Singh, Z. N. (2010) · PubMed · Cited by 178
Sandra, K., Vandenheede, I., & Sandra, P. J. F. (2013) · Journal of Chromatography A · doi:10.1016/j.chroma.2013.11.057 · Cited by 176
Monoclonal antibody-induced cytokine-release syndrome
Bugelski, P. J., Achuthanandam, R., Capocasale, R. J., Treacy, G., & Bouman-Thio, E. (2009) · Expert Review of Clinical Immunology · doi:10.1586/eci.09.31 · Cited by 161
Anaphylaxis to pork kidney is related to Ig E antibodies specific for galactose‐alpha‐1,3‐galactose
Morisset, M., Richard, C., Astier, C., Jacquenet, S., Croizier, A., Beaudouin, E., Cordebar, V., Morel‐Codreanu, F., Petit, N., Moneret‐Vautrin, D. A., et al. (2012) · Allergy · doi:10.1111/j.1398-9995.2012.02799.x · Cited by 164
Metadata
- Authors
- Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., Slebos, R. J., Zhou, Q., Gold, D., Hatley, T., Hicklin, D. J., & Platts-Mills, T. A. E.
- Affiliations
- Vanderbilt University (US)
- Bristol-Myers Squibb (United States) (US)
- Stanford University (US)
- Duke Medical Center (US)
- University of Virginia (US)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-03-13
- Volume
- 358
- Issue
- 11
- Pages
- 1109-1117
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2361129
- OpenAlex
- W2140035322
- Cited by
- 1,521
- References
- 35
- Citations by year
- 2026: 63 · 2025: 79 · 2024: 64 · 2023: 83 · 2022: 78 · 2021: 78 · 2020: 94 · 2019: 80 · 2018: 78 · 2017: 109 · 2016: 90 · 2015: 99 · 2014: 88 · 2013: 97 · 2012: 94
- FWCI
- 57.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Damon Runyon Cancer Research Foundation
- Bristol-Myers Squibb
- Vanderbilt University
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
- National Institutes of Health (20565, 2r01ai020565-29, 5r01ca118582-05, AI-20565)
- U.S. Public Health Service (AI-AADCRC-U19-070364)
- National Cancer Institute (R01-CA-118582, P50CA095103, P50CA95103)
- National Institute of Allergy and Infectious Diseases (AI 20565, R01AI035796, R01AI-020565, AI/EHS-35796, R29AI035796, R37AI020565)
- National Institute of Dental and Craniofacial Research (R01DE017982)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- cetuximab, anaphylaxis, drug hypersensitivity, IgE antibodies, galactose-alpha-1,3-galactose, Fab fragment, monoclonal antibodies, epidermal growth factor receptor, pre-existing antibodies, colorectal cancer, head and neck squamous cell carcinoma
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Anaphylaxis, Antibodies, Monoclonal, Epitopes, Antineoplastic Agents, Cross Reactions, Disaccharides, Female, Humans, Immunoglobulin E, Male, Middle Aged, Protein Binding, Protein Conformation, Case-Control Studies, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.